Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 4:44 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 1,579 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Cutaneous Clear all

Conditions: Dermatologic Diseases, Systemic Diseases With Cutaneous Manifestations
Interventions: Not listed
Lead sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS); NIH
Eligibility: 1 Day to 120 Years
Enrollment: 453 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1996 – 2025
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Oral Cavity Squamous Cell Carcinoma, Recurrent Oropharyngeal Squamous Cell Carcinoma, Recurrent Paranasal Sinus Squamous Cell Carcinoma, Stage III Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8, Stage III Hypopharyngeal Carcinoma AJCC v8, Stage III Laryngeal Cancer AJCC v8, Stage III Lip and Oral Cavity Cancer AJCC v8, Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage III Sinonasal Cancer AJCC v8, Stage IV Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8, Stage IVA Hypopharyngeal Carcinoma AJCC v8, Stage IVA Laryngeal Cancer AJCC v8, Stage IVA Lip and Oral Cavity Cancer AJCC v8, Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IVA Sinonasal Cancer AJCC v8, Stage IVB Hypopharyngeal Carcinoma AJCC v8, Stage IVB Laryngeal Cancer AJCC v8, Stage IVB Lip and Oral Cavity Cancer AJCC v8, Stage IVB Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IVB Sinonasal Cancer AJCC v8, Unresectable Head and Neck Squamous Cell Carcinoma, Unresectable Hypopharyngeal Squamous Cell Carcinoma, Unresectable Laryngeal Squamous Cell Carcinoma, Unresectable Oral Cavity Squamous Cell Carcinoma, Unresectable Oropharyngeal Squamous Cell Carcinoma, Unresectable Paranasal Sinus Squamous Cell Carcinoma
Interventions: Biospecimen Collection, Camonsertib, Computed Tomography, Positron Emission Tomography, Stereotactic Body Radiation Therapy; Procedure · Drug · Radiation
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2029
U.S. locations: 4
States / cities: Duarte, California • Irvine, California • Lexington, Kentucky + 1 more

Conditions: Cutaneous T-Cell Lymphomas
Interventions: TSEBT, TSEBT and pembrolizumab; Radiation · Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 120 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Cutaneous Squamous Cell Carcinoma of the Head and Neck, Healthy Subject, Head and Neck Cancer
Interventions: Biospecimen Collection, Magnetic Resonance Imaging, Quality-of-Life Assessment, Questionnaire Administration; Procedure · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Surgery, Surgical Site Infection, Cutibacterium Acnes, Prosthetic-joint Infection
Interventions: Povidone-Iodine, SURGX Wound Gel; Drug · Device
Lead sponsor: St. Louis University; Other
Eligibility: 18 Years to 90 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Lichen Planus: Cutaneous Lichen Planus, Mucosal Lichen Planus and Lichen Planopilaris
Interventions: secukinumab 300 mg Q4W, secukinumab 300 mg Q2W, Placebo; Drug · Other
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 111 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 15
States / cities: Birmingham, Alabama • Thousand Oaks, California • Cromwell, Connecticut + 12 more

Conditions: Neoplasms
Interventions: feladilimab, Tremelimumab, Docetaxel, Paclitaxel, Cetuximab; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 5
States / cities: Boston, Massachusetts • New York, New York • Pittsburgh, Pennsylvania + 1 more

Conditions: Heat Effect
Interventions: Lidocaine patch; Drug
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years to 45 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Cutaneous Tumors, Mohs Micrographic Surgery
Interventions: Norco 5Mg-325Mg Tablet, Suzetrigine; Drug
Lead sponsor: Baylor Research Institute; Other
Eligibility: 18 Years to 89 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Breast Cancer, Mastectomy
Interventions: AlloDerm RTU, SurgiMend PRS; Device
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older · Female only
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Lupus
Interventions: BMS-986326, Placebo for BMS-986326; Drug · Other
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 7
States / cities: San Diego, California • Clearwater, Florida • Tampa, Florida + 4 more

Conditions: Lupus Erythematosus, Discoid, Lupus Erythematosus, Subacute Cutaneous
Interventions: Deucravacitinib, Placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 12
States / cities: Scottsdale, Arizona • Irvine, California • Los Angeles, California + 9 more

Conditions: Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus (CLE)
Interventions: Enpatoran, Placebo, Standard of care (SoC); Drug
Lead sponsor: EMD Serono Research & Development Institute, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 202 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 12
States / cities: Los Angeles, California • Thousand Oaks, California • Cooper City, Florida + 7 more

Conditions: Brain and Central Nervous System Tumors, Breast Cancer, Kidney Cancer, Lung Cancer, Lymphoma, Melanoma (Skin), Ovarian Cancer, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: carboxyamidotriazole, paclitaxel; Drug
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1994 – 2006
U.S. locations: 2
States / cities: Bethesda, Maryland

Conditions: Diabetic Foot Ulcer
Interventions: Dermal - Living Skin Replacement (Dermal - LSR); Device
Lead sponsor: ApoPharma; Industry
Eligibility: 18 Years to 84 Years
Enrollment: 288 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 12
States / cities: Tuscon, Arizona • Mather, California • San Diego, California + 8 more

Conditions: Photoaging
Interventions: Restylane-L, Vehicle; Device
Lead sponsor: University of Michigan; Other
Eligibility: 30 Years to 50 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Metastatic Malignant Neoplasm in the Lung, Metastatic Melanoma, Metastatic Osteosarcoma, Metastatic Renal Cell Cancer, Sarcoma, Stage IV Cutaneous Melanoma AJCC v6 and v7, Stage IV Osteosarcoma AJCC v7, Stage IV Renal Cell Cancer AJCC v7
Interventions: Aerosolized Aldesleukin, Laboratory Biomarker Analysis; Biological · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 12 Years to 50 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2029
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Epidermis, Ultraviolet Exposure
Interventions: Hybrid sunscreen, Chemical sunscreen, No sunscreen; Drug · Other
Lead sponsor: Good Molecules, LLC; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Acellular Dermal Matrix in Breast Reconstruction
Interventions: AlloDerm, DermACELL; Other
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 2
States / cities: Washington D.C., District of Columbia

Conditions: Wound Heal, Wound of Skin
Interventions: Factorial Assignment; Other
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Breast Cancer, Drug/Agent Toxicity by Tissue/Organ, Lung Cancer, Lymphoma, Ovarian Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: sargramostim, amifostine trihydrate, cisplatin, cyclophosphamide, etoposide; Biological · Drug
Lead sponsor: Scripps Health; Other
Eligibility: 18 Years to 70 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2001
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Lymphoma, T-Cell, Cutaneous
Interventions: Doxycycline, Imiquimod; Drug
Lead sponsor: James J. Peters Veterans Affairs Medical Center; Federal
Eligibility: 30 Years to 89 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Lupus Erythematosus, Photosensitivity Conditions
Interventions: Phototesting; Other
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2018
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Melanoma
Interventions: Biopsy Procedure, Computed Tomography, Dabrafenib Mesylate, Echocardiography Test, Magnetic Resonance Imaging, Multigated Acquisition Scan, Tazemetostat Hydrobromide, Trametinib Dimethyl Sulfoxide; Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 17
States / cities: Aventura, Florida • Coral Gables, Florida • Deerfield Beach, Florida + 11 more

Search by objective public record fields.

Evaluation and Treatment of Patients With Dermatologic Diseases

Testing the Addition of an Anti-Cancer Drug, Camonsertib, to Radiation Therapy for Recurrent Head and Neck Squamous Cell Carcinoma

Pembrolizumab and Total Skin Electron Beam Radiotherapy in Mycosis Fungoides and Sézary Syndrome

Magnetic Resonance (MR) Imaging & Blood Biomarkers for Head and Neck Cancer

SURGX Antimicrobial Gel Versus Povidone-iodine Skin Incision Prep in Total Shoulder Arthroplasty

PoC Study to Evaluate the Efficacy and Safety of Secukinumab 300 mg in Patients With Lichen Planus

GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid Tumors

PK and DPK of Lidocaine Dermal Products

Suzetrigine vs Norco-postoperative Mohs Pain

Acellular Dermal Matrix in Tissue Expander Breast Reconstruction: A Prospective, Randomized, Clinical Trial Comparing SurgiMend PRS and AlloDerm RTU

A Study to Investigate the Safety, Tolerability, Drug Levels and Drug Effects of BMS-986326 in Adult Participants With Different Forms of Lupus

A Study to Evaluate Efficacy and Safety of Deucravacitinib in Participants With Active Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE)

A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease

Carboxyamidotriazole and Paclitaxel in Treating Patients With Advanced Solid Tumors or Refractory Lymphomas

Efficacy and Safety Study in the Treatment of Chronic Diabetic Foot Ulcers

Investigating Age Dependence of Fibroblast and Extracellular Matrix Responses to Cross-linked Hyaluronic Acid Filler in Human Skin

Aerosolized Aldesleukin in Treating Patients With Lung Metastases

A Clinical Study to Evaluate the Efficacy and SPF of Two Test Materials According to an Adaptation of the Guidelines of the FDA Sunscreen Drug Products for Over-the-Counter Human Use

Comparing AlloDerm and DermACELL in Breast Reconstruction

Aesthetic Outcome of Complex Linear Closure vs Second Intention Healing: Below the Knee

Amifostine Followed by High Dose Chemotherapy in Treating Patients With Hematologic Cancer or Solid Tumors

CTCL Directed Therapy

Photoprovocation Testing in Subjects With Cutaneous Lupus

Testing the Addition of the Anti-cancer Drug, Tazemetostat, to the Usual Treatment (Dabrafenib and Trametinib) for Metastatic Melanoma That Has Progressed on the Usual Treatment